flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators FLOW: Kidney outcome results for

Give semaglutide at least twelve weeks at your highest dose to assess its true effects

Among the additional cardiovascular outcomes, only incident peripheral vascular disease or atherosclerosis reached nominal significance across weight loss strata ( P = 0.033

This transparent pricing removes a barrier to proper dose escalation and medical follow-up, allowing your provider to optimize your treatment safely

It's also worth noting that semaglutide may delay gastric emptying, which could theoretically affect the absorption of some oral medicines, though this is likely of minimal relevance to melatonin

The initial dose is typically the lowest available (2.5 mg for tirzepatide, 0.25 mg for semaglutide), specifically designed to let your body adjust to the medication